Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript

Acadia reported Q3 2026 revenue of $342 million, up 22% year over year on an adjusted basis; DAYBUE sales rose 39% to $140 million and NUPLAZID sales rose 12% to $202 million. The company raised DAYBUE full-year sales guidance to $505 million–$520 million and narrowed total revenue guidance to $1.265 billion–$1.295 billion. However, remlifanserin’s Phase II RADIANT primary endpoint missed statistical significance (p=0.0603), despite nominal significance on a secondary endpoint at 60 mg; Acadia plans to focus its Phase III ADP program on that dose. A new DAYBUE dosing-regimen patent is expected to extend U.S. protection through March 2041.

Analysis

Commercial execution is the investable strength; pipeline optionality is not yet a substitute for proof. DAYBUE’s STIX adoption and reported restarts broaden the demand funnel, but management says persistence is similar across formulations, so underwrite convenience and re-engagement—not a demonstrated tolerability-driven reduction in discontinuations. The key test over the next 1–3 quarters is whether volume growth persists as the initial conversion wave matures and European reimbursement replaces Germany’s freely set launch pricing. NUPLAZID’s expanded reach is an investment ahead of conversion: guidance reflects timing, making new-to-brand prescriptions and field-force productivity the near-term scorecard.

The RADIANT primary-endpoint miss keeps a material discount on pipeline value. A nominally positive secondary endpoint and planned design changes do not establish Phase III success; CTAD detail and the Q1 2027 FDA interaction are catalysts, while efficacy remains unvalidated. LBDP and MDD data are largely 2027 events, so they offer little immediate fundamental support. The Nov. 9 NUPLAZID patent appeal is a nearer binary risk: an adverse outcome could alter expected branded durability and increase generic-entry uncertainty. DAYBUE’s new patent is valuable only to the extent the allowed claims withstand challenge and support meaningful exclusivity.

Contrarian angle: fast STIX uptake can look like durable acceleration while partly representing formulation switching; conversely, community-practice penetration and restart headroom may extend growth if new starts remain healthy. Cash lowers financing risk, but does not justify capitalizing management’s peak-sales ambitions as established value. Without valuation and market-expectation data, the quarter supports selective exposure, not an unconditional multiple expansion thesis.

Key Decisions for Investors

• Consider a starter long in ACAD on post-event weakness rather than chasing the earnings reaction; size it as a commercial-growth position, not a de-risked pipeline bet. Reassess after CTAD and the Q1 2027 FDA interaction. No valuation data were supplied to establish fair value.
• Track DAYBUE net-sales volume, restart contribution, and European reimbursement progress over the next 1–3 quarters. Treat slowing growth alongside maturing STIX conversion—or a material deterioration in persistence—as evidence against the $700 million 2028 ambition.
• Treat Nov. 9’s NUPLAZID appeal as a discrete event-risk checkpoint. An adverse ruling would weaken the branded-duration thesis; a favorable outcome would remove one near-term overhang but would not validate the commercial growth targets.
• For NUPLAZID, require new-to-brand prescription growth and improving productivity from newly covered physicians before underwriting the 2028 sales ambition. If reach expands without prescription conversion or guidance is cut, reduce exposure.